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ToxicityRAFT- mediated polymerization, providing control over polymer length and architecture as well as facilitating
post polymerizationmodiﬁcation of end groups, has been applied to virtually every facet of biomedicalmaterials
research. RAFT polymers have seen particularly extensive use in drug delivery research. Facile generation of
functional and telechelic polymers permits straightforward conjugation to many therapeutic compounds while
synthesis of amphiphilic block copolymers via RAFT allows for the generation of self-assembled structures capable
of carrying therapeutic payloads.With the large and growing body of literature employing RAFT polymers as drug
delivery aids and vehicles, concern over the potential toxicity of RAFT derived polymers has been raised. While
literature exploring this complication is relatively limited, the emerging consensus may be summed up in three
parts: toxicity of polymers generated with dithiobenzoate RAFT agents is observed at high concentrations but
notwith polymers generatedwith trithiocarbonate RAFT agents; even for polymers generatedwith dithiobenzoate
RAFT agents, most reported applications call for concentrations well below the toxicity threshold; and RAFT
end-groups may be easily removed via any of a variety of techniques that leave the polymer with no intrinsic
toxicity attributable to the mechanism of polymerization. The low toxicity of RAFT-derived polymers and the
ability to remove end groups via straightforward and scalable processes make RAFT technology a valuable tool
for practically any application in which a polymer of deﬁned molecular weight and architecture is desired.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Synthetic polymers are employed in a variety of biomedical applica-
tions. In addition to structural biomaterials and device components,
polymers may also be used for the controlled delivery of therapeutic
agents. While a diverse range of polymers may be generated by numer-
ous polymerization reactions, radical polymerization is among themost
robust and widely applicable methods. The biggest drawback to con-
ventional radical polymerization (i.e. large dispersity and poor control
over molecular mass) is addressed by the use of living radical polymer-
ization techniques such as Nitroxide Mediated Polymerization (NMP)
[1,2], AtomTransfer Reduction Polymerization (ATRP) [3,4], andRevers-
ible Addition Fragmentation chain Transfer (RAFT) polymerization
[2,5,6]. Alone among these techniques, RAFT polymerization allows
control to be achieved in existing polymerization processes simply by
the inclusion of a single additional compound. Moreover, the use of
potentially toxic metal salts is not required. RAFT also permits the facile
generation of complex structures of polymers including multi-block
copolymers, star polymers, bottle brush polymers, hyper branched
polymer and surface coatings to name a few [6]. RAFT mediated
polymerizations can also generate polymers with a variety of reactive
end-groups, allowing for example the coupling of bioactive molecules,
depending on the design of the RAFT agent itself. These qualities make
RAFT polymerization a very attractive tool for the generation of biomed-
ical polymers. As research into applications involving the interaction of
biological systems with RAFT generated polymers grows, one would
want to be assured that toxicity, for example arising from the presence
of RAFT polymer end groups, was not of concern. Importantly, one
needs to be able to distinguish between any toxicity associated with
the polymer chemistry or design of the molecules (e.g. polymers with
amine side chains designed to interact with negatively charged biolog-
ical molecules in various delivery applications) and any toxicity associ-
ated with the RAFT process per se (such as the presence of RAFT end
groups). There remains few detailed in vivo toxicity studies, however,
as RAFT becomes more widely applied in biological systems, we expect
that this situation will rapidly change.
2. RAFT technology
The compounds thatmediate RAFT polymerizations are referred to as
RAFT agents or sometimes, more generally, chain transfer agents and
take the generic form shown in Fig. 1, consisting of a thiocarbonylthio
group with substituent “Z” and “R” groups [1,5].
Following initial chain transfer reactions, a growing polymer chain re-
places the R group. As the full name suggests, RAFT agents aid in the con-
trol of polymerization via reversible addition across the thiocarbonylthio
group and subsequent fragmentation reactions as seen in Fig. 2 [5,6].
Initiation results in the polymerization of monomer (M) to actively
extending polymer chain Pn* with rate constant kp. The radically termi-
nated chain propagates across the thiocarbonyl group of the RAFT agent
yielding a radical intermediate that may fragment to release the
polymer chain or the R group from the RAFT agent. The liberated R
group radical then re-initiates polymerization, generating an actively
extending polymer chain Pm*. Polymer chains with terminal
thiocarbonylthio groups are dormant, but are in dynamic equilibrium
with active, propagating radical polymer chains. Polymer chains (Pn
and Pm) with terminal thiocarbonylthio groups are dormant; they doFig. 1. General molecular structure of RAFT agent, consisting of a thiocarbonylthio group
with “Z” and “R” substituents.not react directlywith availablemonomer. Only Pn. and Pm. actively par-
ticipate in polymerization reactions, but these propagating radicalsmay
chain transfer to dormant thiocarbonylthio compounds, becoming dor-
mant themselves while activating previously dormant chains.
The equilibrium between active propagating chains and dormant
thiocarbonylthio-bound chains provides equal probability for all chains
to grow, resulting in polymers with narrow molecular weight
dispersities [5,6]. When a typical RAFT polymerization is concluded, a
large majority of the polymer chains generated will contain the dor-
mant thiocarbonylthio group, permitting subsequent block extension
of polymers grafted from the original polymer.
RAFTmediated polymerization takes advantage of the initiation and
polymerization conditions of the unmediated radical polymerization
techniques; only the addition of an appropriate quantity of RAFT agent
to a polymerization mixture is necessary to achieve molecular weight
and dispersity control. RAFT mediated polymerization is, therefore,
amenable to radical thermal, redox [7,8] and photochemically initiated
[9,10] polymerizations. Furthermore, scale up protocols such as the
use of continuous ﬂow reactors, are readily adapted to accommodate
RAFT control [11] and end group removal [12].
The identity of the R and Z groups affect howwell this equilibrium is
met and maintained, which determines the quality of the control
achievable in any given polymerization reaction. Because the kinetic be-
havior among the different classes of monomers varies, different RAFT
agents are generally required to control the respective polymerizations
[13,14]. Suitable substituents for various monomers are presented in
Figs. 3 and 4. Many versatile RAFT agents, as of the time of writing, are
commercially available and many more have been reported in the
polymer research literature [6,15–17]. In addition, the RAFT agent selec-
tion rules have been well described in the literature [6] a summary of
which is presented in Figs. 3 and 4 for the Z and R groups respectively.
A detailed discussion of which substituents permit controlled poly-
merization of whichmonomers, and the according theoretical explana-
tions have been presented in previous publications and a number of
review articles and will not be repeated here [1,6,13,14,16,17]. It does
merit mention, however, that recently, switchable RAFT agents, which
change activity depending on the acidity of the polymerization reaction
mixture, have been shown to be effective for the control of both activat-
ed and less activated monomers [18,19]. This brings the concept of a
universal RAFT agent one step closer to reality. As the thiocarbonylthio
RAFT groups remain following polymerization, various advantageous
polymer structures and architectures can be obtained via consecutive
polymerizations with RAFT agents of variable functionalities. Linear
polymers can be synthesized with multiple blocks [20] (Fig. 5). One re-
cent report demonstrated the synthesis of a polymer with 12 distinct
blocks [21]. By this consecutive polymerization of chains of determined
molecular weights, RAFT polymerization has given researchers control
over the sequence of blocks within a polymer, if not of individual
monomer units.
With multifunctional RAFT agents star and graft copolymers can be
obtained (Fig. 6) [22].
Due to the versatility of architectures obtainable with RAFT poly-
merization, it is possible to design and produce synthetic polymers
that resemble, with respect to architecture and chemistry, and which
interact with or mimic the behaviour of natural biopolymers in a
number of critical, functional aspects.
3. RAFT polymers in drug delivery
3.1. Polymer-drug conjugation and grafting
Utilizing of the advantageous characteristics of RAFTmediated poly-
merization and/or the chemical composition and structure of resulting
polymers that may be achieved; various schemes have been successful-
ly applied to aid in the delivery of therapeutic agents. Drug-polymer
conjugates, which may have better pharmacokinetic or solubility
Fig. 2. Scheme of reversible addition-fragmentation chain-transfer (RAFT) polymerization.
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(attaching poly(ethylene glycol) or PEG) of therapeutic agents is the
typical approach taken to generate drug-polymer conjugates with
improved pharmacokinetics. Recently, however, there has been an
emerging trend away from PEG resulting from its oxidative instability
and potential to cause immune response [23].
RAFT agents have been synthesized with a variety of functional
groups at both their R and Z substituents [6]. While such reactive
handles can be present at either or both locations, the R groups is
often preferred because of the lower inherent stability of the
thiocarbonylthio group that binds the Z group to the synthesized
polymer. RAFT agents with orthogonally reactive moieties (see Fig. 7
for some examples) can be used to generate homo or copolymers with
a reactive handle for subsequent conjugation to small molecule drugs,
peptides or larger bio-macromolecules. Alternatively, the RAFT agents
can be conjugated to the therapeutic agent for subsequent direct
polymer grafting from reactions. An example of the former, Tao et al.
[24] generated an amine-reactive RAFT polymer via polymerization of
poly(N-(2-hydroxypropyl) methacrylamide) (poly(HPMA)) with a
thiazolidine-2-thione functionalized RAFT agent. The polymer was
conjugated via amide bond formation via incubationwith themodel pro-
tein (lysozyme). Because of their ubiquity in proteins, amines are an obvi-
ous choice for bioconjugation of polymers and so amine-reactive handles
(e.g. succinimidyl esters, pentaﬂuorophenyl esters, thiazolidine-2-thione)
are often included on RAFT agents. Thiol-reactive RAFT agents are also
popular for the same reason. Davis and coworkers [25] synthesized a
bis-trithiocarbonate RAFT agent with a pendant pyridyldisulﬁde in the
middle. Polymerization of HPMA resulted in a linear homopolymer of de-
termined molecular weight with a centrally located reactive handle for
subsequent conjugation to a cysteine thiol on the model protein (BSA).
The advantage of the mid-chain conjugation, readily achieved via RAFT
polymerization, is the “umbrella effect” that it provides, more effectivelyFig. 3. Non-exhaustive list of RAFT Z groups and the mmasking the protein surface from approaching macromolecules
(e.g. proteases). Conjugation of random and block copolymers, synthe-
sized via RAFT techniques, allows for a less passive delivery mechanism.
The polymers may serve multiple functions in order to actively affect
how and where a therapeutic payload is delivered. Duvall et al. [26]
generated a di-block copolymer via RAFT for conjugation to a
proapoptotic peptide, a potential anti-cancer agent. The RAFT agent
employed contained a pyridyl disulﬁde for subsequent attachment via
a terminal cysteine on the peptide. The initial block consisted of
poly(HPMA) to impart aqueous solubility to the conjugate while the sec-
ond block was composed of equimolar quantities of dimethylaminoethyl
methacrylate (DMAEMA), propylacrylic acid (PAA), and butyl methacry-
late (BMA) as a random copolymer. The diblock copolymer was demon-
strated to undergo a pH-dependent transition from inert at pH = 7.4 to
membrane-disruptive at decreased pH (pH = 5.8), providing a
mechanism for endosomal escape and intracellular delivery of the
bioactive peptide.
An example of direct grafting from a protein was provided by De
et al. [27], wherein the authors covalently linked a maleimide-bearing
RAFT agent to a free thiol side chain of a cysteine residue in the model
protein (BSA). Polymerization of N-isopropylacrylamide (NIPAM)
was performed in aqueous buffer with water soluble initiator 2,2′-
azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044).
3.2. Intrinsically bioactive polymers
Synthetic polymers themselves may act as therapeutic agents. Some
biologically active moieties have improved efﬁcacy when structured in
clusters on a single macromolecule (polyvalency). Additionally, higher
molecular weights may improve the effective therapeutic dosage by
mitigating toxicity and clearance relative to small-molecule analogues.
Broad molecular weight dispersities and compositional heterogeneityonomers for which they are most appropriate.
Fig. 4. Non-exhaustive list of RAFT agent R groups and the monomers for which they are appropriate.
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regulatory approval [34]. Despite their promise, therapeutic polymers
are viewedwith a degree of skepticism in the drug discovery communi-
ty. Controlled radical polymerization techniques, such as RAFT, can
generate polymers with more uniform dispersities and deﬁned compo-
sitions, directly addressing principle concerns of medicinal chemists.
Talelli et al. [35] recently demonstrated that micelles, formed from
copolymers of PEG and N-(2-hydroxypropyl) methacrylamide-lactate,
exhibited intrinsic anti-tumor activity in the absence of the anti-
cancer drug the micelles were designed to carry. While the copolymers
used in this study were generated via another radical polymerization
technique, RAFT represents a means to generate similar polymers to
study the bioactivity and therapeutic potential of synthetic polymers.
Cationic polymers in general providemany examples of intrinsically ac-
tive polymers. Poly(L-lysine) dendrimers may have anti-angiogenic
properties [36]. Lee et al. [37] demonstrated that some cationic
polymers could have anti-inﬂammatory effects by scavenging and thus
preventing the receptor binding of immune stimulatory nucleic acids.
While polymers-as-drugs research is relatively new, it is not difﬁcult to
see where RAFT polymerization can aid in the synthesis of bioactive
polymers. Already, polymerizable analogues of biofunctional groups
have been used to generate RAFT polymers with intrinsic therapeutic ef-
fect. Locock and coworkers [38–40] designed a series of amphiphilic,
amine and guanidine-bearing polymers to mimic naturally occurring
anti-microbial peptides. RAFT-mediated polymerization allowed copoly-
mers of low dispersity and various molecular weights to be synthesized.
The authors demonstrated particularly low hemolytic activity and high
antimicrobial activity against Staphylococcus epidermidis and Candida
albicanswith low molecular weight guanidine copolymers.
3.3. Stimuli-responsive polymers
Polymers may be designed to respond to biological cues that result
in the delivery of a therapeutic payloadwithin an appropriate biologicalFig. 5. Examples of linear polymers that can be obtained via RAFT polymerizations.context. Duvall's pH responsive di-block copolymer, previously described,
is one example. RAFT is often used to generate thermally responsive poly-
mers for drug delivery. Foremost among thermally responsive polymers
is poly(NIPAM), which, in aqueous media, exhibit hydrophobic behavior
and aggregate at temperatures above its lower critical solution tempera-
ture (LCST) of 32 °C, but remain hydrophilic and soluble at lower temper-
atures. This behavior has been exploited for the proposed delivery of
therapeutic compounds. De et al. [41] used an azide functionalized
trithiocarbonate RAFT agent to synthesize azido-terminal copolymers of
dimethylacrylamide (DMA) and NIPAM, which were then conjugated to
alkyne-functional propargyl folate via copper-catalyzed azide-alkyne cy-
cloaddition. Dipyridamole (a model hydrophobic drug) was loaded into
hydrophobic polymer aggregates by stirring in an aqueous suspension
at 50 °C. While rapid and complete release of the drug was expected
and observed at temperatures below the LCST, aggregates more slowly
released the drug at 37 °C. Taking advantage of another temperature re-
sponsive polymer, Sun et al. [42] exploited the amenability of RAFT to
surface grafting reactions in order to generate polymer-decorated silica
nanoparticles. Following attachment of a RAFT agent to silica nanoparti-
cles, DMAEMA polymer was grafted from the surface. A fraction of the
tertiary amines were then quaternized with 1,3 propanesulfone to gen-
erate a random copolymer with both cationic and zwiterionic residues.
Rhodamine Bwas loaded at room temperature onto the surface polymer
brush and then released at 37 °C when the swollen polymer brush col-
lapsed and expelled its payload.
3.4. Self-assembled, drug-loaded structures
Another way in which RAFT polymers are often applied in drug
delivery is via self-assembled structures or complexes. AmphiphilicFig. 6. Examples of star and graft copolymers obtainable via RAFT polymerizations.
Fig. 7. General structure of RAFT generated polymer with R and Z terminal groups dictated by RAFT agent with examples of RAFT agents with terminal functional moieties. From top to
bottom, left to right: hydroxyl [28], carboxylic acid [28], succinimidyl ester [29], boc-protected amine [28], azide [30], alkyne [31], norbornene [33], pyridyl disulﬁde [31],
pentaﬂuorophenyl ester [31] and biotin [32].
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that can complexwith therapeutic agents to protect against degradation
and to encourage delivery to the appropriate biological environments,
including intracellular delivery. This technique is particularly useful
for the delivery of hydrophobic drugs that partition to the hydrophobic
interior ofmicelles and other structures. Onedrawback to this approach,
however, is the inherent instability of the self-assembled structures,
which, depending on temperature and concentration, may dissociate
prematurely. Several approaches have been taken to prevent this from
happening. Chan et al. [43] provides a good example of how block copo-
lymerization, via RAFT, was used to generate polymeric nanoparticles ca-
pable of delivering anti-cancer drug doxorubicin. Researchers synthesized
an amphiphilic diblock copolymer with poly(hydroxyethyl acrylate) as
the ﬁrst block followed by poly(n-butyl acrylate). The resulting block co-
polymer was allowed to formmicelles in aqueous media in the presence
of a hydrophobic crosslinker and radical initiator. The micelles formed
around crosslinker, whereupon radical initiation and addition to the
thiocarbonylthio group resulted in the generation of a crosslinked core,
improving the stability of the micelles. Liu et al. [44] used a similar tech-
nique to improve micelle stability, while incorporating a mechanism for
micelle dissolution and drug release at lower pH values such as those
found in tumor tissue. RAFT was used to synthesize a polymer of PEG ac-
rylate (MW= 350 g/mol). Subsequently the chain was extended with
vinyl benzaldehyde and N-N′-bis(acryloyl) cystamine, a diacrylamide
with a disulﬁde linkage. The resulting polymeric nanoparticles presented
a hydrophilic, brush-type exterior with a pH sensitive degradable hydro-
phobic core with aldehyde groups for the attachment of the doxorubicin.
In vitro experiments demonstrated the effective delivery of the drug to
SY5Y and MRC5 cell lines.
Du et al. [45] also used RAFT polymerization to deliver doxorubicin,
taking advantage of the pH sensitivity of the acetal functionality in the
middle section of an ABC-type tri-block copolymer. The tri-block copol-
ymer formed a polymersome with the doxorubicin on the interior.
When the acetals were cleaved at low pH, the polymersome swelledand released the drug. The authors demonstrated targeted delivery to
HeLa cells.
3.5. RAFT polymers in nucleic acid delivery vehicles:
RAFT polymers have been found to be particularly useful in the de-
velopment of vehicles for the intracellular delivery of nucleic acids, in
particular small interfering RNA (siRNA). Cationic polymers can bind
to negatively charged nucleic acids forming complexes that prevent en-
zymatic degradation of the DNA and resulting in reducing repulsive
electrostatic interactions at the cellular interface that would normally
be present for DNA alone, thus facilitating uptake by the cells. The
cationic polymers themselves, however, exhibit both immediate and
delayed cytotoxicity viamembrane disruption and interferencewith in-
tracellular growth-associated processes. Complexation of the cationic
polymers with anionic nucleic acids can decrease, but not eliminate
these effects. Unfortunately, both cellular uptake of the polymer-
nucleic acid complex and cytotoxicity are positively correlated with
molecular weight and charge density of the polycation. Higher order
structures of lowermolecular weight block copolymers (easily generat-
ed by RAFT polymerization), such as micelles and vesicles, often
mitigate cytotoxicity while improving nucleic acid delivery.
As siRNA delivery is one of the most promising therapeutic applica-
tions of RAFT mediated polymerization, there have been numerous
evaluations of the cyto-compatibility of the copolymers used in this
application and generated via the RAFT process. In the case of nucleic
acid-complexing polymers, RAFT-mediated polymerization represents
a means whereby the intrinsic cytotoxicity of polymers can be lessened
by rational design of polymers, which is achievable by ﬁne-tuning the
molecular weight, architecture and composition.
Hinton et al. [46] generated ABA (PEG methacrylate (PEGMA),
quaternized DMAEMA, PEGMA) tri-block copolymers of with blocks of
various lengths via RAFT mediated polymerization. Unsurprisingly, the
authors observed increases in gene silencing as well as increases in
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gene silencing (comparable to that obtained for a commercially
available control material, Lipofectamine 2000) was achieved for sever-
al triblock copolymers below their toxicity threshold concentrations
(deﬁned as the concentration of non-complexed polymer at which
cells exhibited 80 % or greater viability in 72 hour culture). The control
that RAFT techniques provide, make possible the synthesis of polymers
with narrowly disperse molecular weights of sufﬁcient size for cellular
uptake, with the advantage that they can be produced at low enough
molecular weights to minimize cellular morbidity. RAFT-mediated
polymerizationwas used in this study as a tool to create polymer librar-
ies against which toxicity and efﬁcacy could be evaluated to determine
appropriate structures and compositions.
Siegwart et al. [47] generated an extensive library of core-shell
nanoparticles by the combinatorial reaction of sixteen RAFT generated
glycidyl methacrylate block copolymers with 96 distinct multifunction-
al amines (1536 unique compositions ofmicroparticles). In vitro gene si-
lencing and toxicity was assessed bymeasuring the expression of ﬁreﬂy
luciferase, against which siRNA was applied, and RenillaI luciferase,
against which no siRNA was applied. Depletion of ﬁreﬂy luciferase
with no depletion of Renilla luciferase would indicate effective and
nontoxic gene silencing while depletion of both would indicate a toxic
effect. In a similar fashion to Hinton et al., Siegwart employed RAFT as
a means of generating, with relative ease, a variety of block copolymers
in order to identify effective and cyto-compatible nucleic acid vectors.
Twenty-seven compositions were found that showed siRNA delivery
equivalent to Lipofectamine 2000. Some compositions were effective
DNA delivery vehicles as well with one that exhibited a greater than 6
fold increase in intranuclear DNA delivery relative to the commercial
Lipofectamine transfection agent.
More recently, Boyer et al. [48] synthesized cationic star polymers by
initially generating the arms via RAFT polymerization of DMAEMA
with a dithiobenzoate and then synthesizing the core via RAFTmediated
copolymerization with a relatively small amount of a disulﬁde
bisacrylamide. The result was star polymers that were reductively de-
gradable. The authors performed cytotoxicity tests against MiaPaCa-2
pancreatic cancer cells and H460 non small cell lung cancer. Neither
the star polymers alone, nor when complexed with siRNA, resulted in
any observable toxic effects at approximately 1 μM concentration of
RAFT groups at 24 hours. The same concentration of polymer/siRNA
complex resulted in 60–80% silencing of gene expression. Many more
studies of nucleic acid delivery in vitro have been published. TwoFig. 8. Schematic illustrating various general modes of polymer cytotoxicity. Clockwise from top
small molecules; polymer interacts with and disrupts cellular membrane; polymer interferes wcommon themes among the broader body of literature are 1) control
over molecular weight and polymer architecture can mitigate the
intrinsic toxicity of membrane-disrupting polymers [49,50] and
2) RAFT polymerizations can be used as means to generate many poly-
mers of varying sizes and compositions to optimize cyto-compatibility
and delivery [46,47].4. RAFT-derived polymer toxicity
4.1. Modes of polymer toxicity
Because of themany applications of RAFT generated polymers in the
biomedical ﬁeld, potential for toxicity is a concern. Theoretically, a
polymer may cause cell damage or death via one or more general
modes as illustrated in Fig. 8. Impurities from the polymerization reac-
tionmay adversely affect biological systems. The presence of potentially
toxic impurities is a result of virtually all polymerization reactions as the
monomers used to generate biocompatible polymers are themselves
often highly toxic (e.g. PEG and ethylene oxide, polyacrylamide and
acrylamide). Catalysts (e.g. redox couples or copper salts used in copper
catalyzed, azide alkyne cycloaddition (CuAAC) or ATRP reactions),
initiators and other polymerization aids (e.g. RAFT agents) may also
be sources of toxic impurities.
With adequately puriﬁed polymers, chemical degradation could
release toxic, small molecules that, as a bound component of a large
molecular weight species, cause no cellular toxicity. Used as a tissue
adhesive, cyanoacrylate polymers, for example, may release cytotoxic
levels of formaldehyde during degradation [51]. This general mode of
toxicity is also relevant to RAFT polymers, particularly as the
thiocarbonylthio moiety may be prone to hydrolysis.
Alternatively, the polymer itself, or constitutive elements thereof, by
virtue of the polymer's very composition, could interact with and dis-
rupt cellular membranes. In fact, many cationic polymers cause cell
death by this mechanism and this is the general mode of action of
polymers designed to be antibacterial in nature. Themost consequential
variables in this scenario are the chemical character of the monomer
and the molecular weight of the polymer, which may be tuned via
RAFT mediated techniques, rather than the particular mechanism of
polymerization. However, it is worth noting that RAFT agents dictate
the terminal moieties of the resultant polymer, which may have an
inﬂuence on biointerfacial interactions.: polymer containing toxic small molecule impurities; polymer degrades to generate toxic
ith intracellular processes (e.g. mitochondrial membrane disruption).
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virtue of their molecular weight, composition or architecture, could in-
terfere with intracellular processes. Poly(ethylenimine), for example,
exhibits not only immediate cytotoxicity, due to the disruption of the
cellular membrane, but also delayed cytotoxicity via disruption of
mitochondrial membranes thereby triggering apoptosis [52].
Regardless of themechanism, any potential toxic effects attributable
to the RAFT agent would depend on the interactions between the
biological elements, the molecular structure of the RAFT polymer end
groups, the chemical and physical properties of the polymer and the
speciﬁc biological context in which the polymer is applied. This
complexity makes it difﬁcult to deﬁnitively categorize RAFT-generated
polymers and, more generally, RAFT agents as either biocompatible or
non-biocompatible. The following summarizes and highlights observa-
tions from the published literature pertaining to the interaction of
RAFT-derived polymers with biological systems to generate some
guidelines for the employment of such polymers in biological context
and to identify some of the key literature where the RAFT process has
been safely employed in biological applications. While there are RAFT
agents with a variety of Z groups, in the generation of biomedical
polymers, dithiobenzoates and trithiocarbonates (shown in Fig. 10) are
themost prevalent. Also, with some notable exceptions,most of the poly-
mers generated are poly(meth)acrylates and poly(meth)acrylamides.4.2. Mitigating potential toxicity via pre-emptive removal of RAFT end
groups
Where it has been observed, the toxicity of RAFT-derived polymers
has generally been attributed to the cleavage of the thiocarbonylthio
groups. RAFT agents are sulfur analogs of esters designed to readily un-
dergo radical homolysis between the thiocarbonylthio and the R group
(or the resulting polymer). Because that bond is necessarilyweak, those
moieties prone to radical homolysis may also be prone to hydrolysis
[53]. Hydrolytic susceptibility is further exacerbated by increases
in temperature and pH [53,54]. For this reason many workers
pre-emptively remove the thiocarbonylthio group of the polymer [55].Fig. 9. A scheme illustrating several common RAFT-group removal techniques. From top: therm
and in situ nucleophilic replacement.The Z and R group substituents determine, to a large degree, the
stability of the thiocarbonylthio group. Therefore, the potential for the
degradation of RAFT groups from various polymers will depend not
only on the particular RAFT agent employed, but also on the monomer
polymerized. For heat stable polymers, the simplest RAFT removal
method may be thermal. The thiocarbonylthio group can rapidly
decompose at temperatures from 120 °C to 200 °C. But these elevated
temperaturesmay be undesirable for polymerswith thermally sensitive
pendent groups or conjugated compounds, common in polymers and
polymer conjugates designed for biomedical applications.
Fortunately, several other fast and facile RAFT group removal
processes exist that don't require expensive reagents, or harsh condi-
tions. For example, addition of excess radical initiator will fragment
and replace the thiocarbonylthio group. Inclusion of an appropriate
hydrogen donor during the reaction will result in substitution with a
hydrogen atom rather than an initiator fragment. A number of these
approaches are summarized in Fig. 9.
Aminolysis of the RAFT group can yield a terminal thiol for subse-
quent reactions. Under oxidizing conditions, aminolysis can also gener-
ate disulﬁde-linked polymer dimers. Inclusion of thiol-reactive species
(e.g. halides and Michael acceptors) can be utilized either to cap the
polymer end group or introduce a new terminal functional group. In
the case of acrylates, acrylamides, methacrylates and methacrylamides,
this can often be carried out with the addition of amine to the polymer-
ization reactionmixturewith unreactedmonomer acting as theMichael
acceptor to cap the polymer's Z terminus.
While the above-mentioned RAFT-group removal techniques are
generally the most common, there are others methods not described
here. Several reviews present detailed discussions of the subject
[56–58]. The chemical structure of various polymers created using
common monomers and RAFT agents is illustrated in Fig. 10.
4.3. Studies of the In vitro toxicity of RAFT polymers
Few studies have examined the cytotoxicity of RAFT mediated
polymers directly. Chang et al. [59] examined the cellular mortality
rates of mouse embryonic ﬁbroblast cells (NIH 3 T3) incubated witholysis, addition fragmentation coupling, radical induced reduction, nucleophilic removal,
Fig. 10. A) A trithiocarbonate RAFT agent and polymer resulting from reaction with
(meth)acrylates or (meth)acrylamides and B) dithiobenzoate RAFT agent and polymer
resulting from reaction with (meth)acrylates or (meth)acrylamides. For methacrylate
and methacrylamides, Y = CH3. For acrylates and acrylamides, Y = H. For acrylates and
methacrylates X = oxygen-bound substituent. For acrylamides and methacrylamides,
X = nitrogen-bound substituent.
Fig. 11. A) RAFT-conjugated PEG used in Shen et al. and B) RAFT-generated poly(PEG
methacrylate) used in Shen et al. [62].
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from approximately 20–700 μM). All compounds were polymers of
PEG-methacrylate and ranged in molecular weight from 14 kg/mol to
39 kg/mol. Trithiocarbonate and dithiobenzoate RAFT groups were
used as well as a tertiary bromide for the generation of an ATRP
polymer. The authors observed no cytotoxicity for the trithiocarbonate
polymers, but substantial toxicity for the dithiobenzoate polymers at
the higher concentrations. The mode of toxicity hypothesized by the
authors involved the hydrolytic release of cytotoxic RAFT fragments;
the trithiocarbonate RAFT agents were more hydrolytically stable and
thus less cytotoxic. Aminolysis and protection of the resulting thiol
completely mitigated the toxicity of the dithiobenzoate polymers. For
comparison, ATRP polymers puriﬁed by aluminum oxide column and
repeated precipitation exhibited toxicity at higher concentrations,
presumably due to the presence of copper ions not removed in the
puriﬁcation steps. Dialysis against water reduced the concentration of
impurities to a non-toxic level.
To date, Pissuwan et al. provides the most extensive evaluation of
RAFT polymer toxicity in vitro. Pissuwan et al. [60] investigated
the effect of RAFT polymers on three different cell types: NIH 3 T3,
chinese hamster ovary cells (CHO-K1) and murine macrophage cells
(Raw264.7). Like Chang et al., Pissuwan focused on polymers made
using dithiobenzoate and trithiocarbonate RAFT agents and conﬁrmed
the prior observations with respect to trithiocarbonate terminated
RAFT polymers. However, where Chang et al. noted cytotoxic effects of
PEG and HPMA dithiobenzoate polymers, Pissuan et al. reported con-
ﬂicting results for a poly(PEG acrylate) despite the use of a similar
dithiobenzoate RAFT agent and the same cell line.
Pissuwan et al. did observe relatively high cytotoxicity, however, for
dithiobenzoate RAFT polymers of HPMA solutions at high concentra-
tions among all cell types. Notable was the apparent absence of a linear
response to dosage. No cytotoxicity was indicated at a concentration of
200 μMwhile a dose of 500 μMRAFT polymer resulted in 80% cell death,
indicative of a threshold concentration for toxicity. This was consistent
with results from Gibson et al. [61] who observed no decrease of cell
viability with human endothelial cells (EaHy 926) cultured with up to
275 μM dithiobenzoate-terminated p(HPMA). Recognizing that
polymers in a physiological environment may degrade by processes
other than hydrolysis, Pissuwan et al. also examined the toxicity of
RAFT-generated polymers that had been exposed to a mixture of
metabolic enzymes (rat liver S9 fraction) commonly used in the assess-
ment of drug metabolism. No decrease in viability was observed after
72 hours of incubationwithmetabolic products of either dithiobenzoate
or trithiocarbonate terminated PEG methacrylate polymers at concen-
trations up to 1000 μM.While Pisswan et al. [60] and Chan reported conﬂicting observations
with regards to the potential toxicity of dithiobenzoate-terminated
PEG-(meth)acrylate polymers, both reported high viability of various
cell types cultured with up to 1 mM trithiocarbonate-terminated
polymers. Shen [62], however, reported less than 60 % viability of a
lung cancer cell line A549 when exposed to 200 and 400 μM solutions
of a RAFT agent conjugated to PEG (5 kg/mol). This study seems to be
alone in the suggestion that there may be some toxicity associated
with trithiocarbonate-terminal polymers in in vitro cell culture. Howev-
er because the RAFT agent was simply conjugated to the polymer, the
bond between the trithiocarbonate and the R group was not one that
would be generated in a RAFT-mediated polymerization of (meth)acry-
lates or (meth)acrylamides. Thus, this structure is not directly compara-
ble to that of the other polymers examined in the study (see Fig. 11).
Rather, such a bond, whilst not uncommon in RAFT agents themselves,
would be produced by the polymerization of the relatively uncommon
(for biomedical applications) methacrylonitrile. Thomas et al. [53] ex-
amined the rate of hydrolysis of the dithiobenzoate RAFT agent with a
similar R group and found it approximately 10 times greater than the
dithiobenzoate terminus of the polyacrylate generated with the same
RAFT agent. It may very well be the case that trithiocarbonate terminal
polymers are similarly less hydrolytically labile than the cyano-R-
group-bearing RAFT agents used to generate them.
To explain the disparity in cytotoxicity between the PEG-conjugated
trithiocarbonate RAFT agent and an apparently non-toxic poly(PEG
methacrylate) generated with a similar RAFT agent, Shen et al. hypoth-
esized that the RAFT end groups attached to linear polymers might be
more susceptible to hydrolysis than the RAFT groups on nonlinear,
brush-like polymers because of steric congestion. While steric effects
may be a mitigating factor when it comes to RAFT end group degrada-
tion, the authors do not present adequate evidence of such by compar-
ing the toxicity of two chemically dissimilar trithiocarbonates. Even
though ﬂaws in experimental design limit the insight into cytotoxicity
of RAFT agents that may be gleaned from this paper, it is relevant
to the discussion herein in that it demonstrates at least one
trithiocarbonate compound with an apparent cytotoxic effect. Whilst
it is a trithiocarbonate moiety that would not be present on most
RAFT-generated polymers, it serves to demonstrate that RAFT agent
toxicity, even if the RAFT moiety is conjugated to a polymer, may
substantially differ from RAFT-polymer toxicity.
There is an extensive deﬁcit in the literature regarding explicit study
of RAFT agent toxicity. While a few studies have investigated the toxicity
of RAFT-generated polymerswith trithiocarbonate or dithiobenzoate ter-
mini, whole classes of RAFT agents (e.g. xanthates and dithiocarbamates)
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dithiobenzoate-terminal (meth)acrylate polymers exhibit some toxicity
at concentrations of hundreds of micromolar, possibly resulting from
the more hydrolytically labile RAFT moiety. This observation could sug-
gest that some polymers with terminal xanthates, which are also hydro-
lytically susceptible [63] might show a similar cytotoxicity proﬁle in vitro.
Increased cellular death is not the only potential consequence of ex-
posure to the RAFT end groups. It is certainly possible that low
concentrations of thiols and other potential degradation products of
RAFT agents could interfere with cellular function with manifestations
other than cell death. A hypothetical pathway for such an effect might
be through interaction with and inhibition of sulfur-containing biomol-
ecules. Of course, the sheer number of such potential interactions is vast
and thesemore subtle possible effects of RAFT agents, either short term
or long term, have yet to be explored.
Michl et al. [40] examined the effect of R and Z groups of
trithiocarbonate RAFT agents on the haemolytic activity of RAFT derived
antimicrobial copolymers. The motivation of this and earlier works
[39,64] was the generation of polymers with antibacterial and antifun-
gal properties, yet with minimal toxicity or haemolytic activity towards
mammalian tissue. While Chang and Pissuwan observed cytotoxicity,
which was dependent on the Z group present, Michl observed dramatic
effects on haemolysiswith polymers of differing R groups. These antimi-
crobial agentswere copolymers ofmethylmethacrylate and aminoethyl
methacrylate or a guanidinium-modiﬁed version of that same polymer.
Haemolysis due to the amine copolymer was reduced by a factor of 20
when a cyanopropyl R group was replaced with a cyanovaleric acid
(see Fig. 12). The haemolysis was statistically reduced in the case of
the guanidinium copolymer as well, though only by roughly 50 %. This
appears to be a special case, however; the results should not be extrap-
olated to suggest that acid-bearingR groupswill always, or even typical-
ly, be less toxic than their neutral analogues. The authors hypothesized
that the anionic terminal functional group exerted a greater-than pro-
portional inﬂuence on polymer chain aggregations (each polymer
chain contained approximately 17 pendant cationic groups and only
one terminal carboxylate), altering the interaction between the cationic
polymer chains and the red blood cells. These effects should not be
considered RAFT-speciﬁc; one might expect that this result would be
obtained if the polymer's terminal carboxylic acid were the result of
RAFT mediated polymerization or any other chemical process. While
this haemolytic activity seems to be a unique example of R-group effect
on cellularmembranes, it is a good demonstration of the fact that choice
of RAFT agents dictates terminal groups of the polymer, which can have
substantial and disproportionate effects on the interactions of those
polymers with biological systems.
Many of those studies addressed so far (e.g. Chan, Pissuwan, Gibson,
Shen) have explored toxic effects of RAFT generated polymers at con-
centrations at hundreds to thousands of micromoles per litre. It should
be noted that these concentrations often vastly exceeded the concentra-
tion at which the polymers were used, in other studies, to facilitate drug
delivery or otherwise elicit a biological response. Many studies existFig. 12. Structures of polymers used in study byMichl et al. RAFT-generated cationic polymers w
analogous polymers without terminal acid.[65–73] that demonstrate the therapeutic window for RAFT polymer-
drug conjugates/complexes well below the threshold toxicity.4.4. Biological interactions at surfaces
While the application of RAFT-generated soluble polymers in bio-
medical ﬁelds dominates the literature, the technology has great prom-
ise in the fabrication and modiﬁcation of solid devices as well. RAFT
techniques permit grafting from virtually any surface (e.g. metallic, ce-
ramic, polymeric) to generate appropriate chemical cues at biological
interfaces. Additionally, block copolymers may form materials with
nanomeric or microscopic features that may beneﬁcially inﬂuence the
performance of a device in a biological context.
While toxicity from exogenously delivered RAFT polymer in cell in
culture represents a relatively simple scenario with well-deﬁned pa-
rameters (e.g. concentration of polymer, duration of exposure) the in-
teraction at the surface of a solid material is more complex. With a
solid material, the potential for release of toxic small molecules is still
present whether via extraction of impurities or chemical degradation.
If degradation, extraction, or slow dissolution of the polymer material
is taking place, the concentration gradient generated may affect how
the cytotoxic response is manifested. The physical features or form of
the solid (e.g. smooth, rough, ﬁbers, sponge, etc.), dictating the surface
area available for cellular interaction as well as for extraction, also will
have a large effect on the potential cytotoxicity of the material. In the
absence of leachable material or solubilizing polymer, membrane dis-
ruption is limited to the surface of the material, but the concentration
of the polymer at that surface is extremely high relative to exogenously
delivered polymer.
Few studies have examined the toxicity of solid, RAFT generated
or RAFT polymer coated materials. Beattie et al. [74] generated
honeycomb-structured porous materials from amphiphilic block
copolymers of styrene and acrylic acid. The di-block copolymers were
generated with a trithiocarbonate RAFT agent, the poly(acrylic acid)
composing the second block. Filmswere cast on either glass or polypro-
pylene substrates and, following washing, were extracted with cell
media. Extracts were then added to conﬂuent L929 mural ﬁbroblast
cells on TCPS, whichwere then cultured for 48 hours, and subsequently
assayed for growth inhibition. For extracts from polymer-coated glass
surfaces, no inhibition was observed, while some growth inhibition
was observed for the polymer-coated polypropylene surfaces. This ﬁnd-
ing suggested that it was materials that had leached from the base sub-
strate and not from the RAFT polymer ﬁlm on top that were toxic to
cells. Cells cultureddirectly on the honeycomb-patterned RAFT polymer
surface exhibited no elevated cell death, suggesting no cytotoxicity
attributable to the RAFT polymers against cells in direct contact with
the material.
A subsequent study [75] from the same group observed reported no
cellular mortality with L929s cultured on similar RAFT generated hon-
eycomb structures grafted with poly(NIPAM) via RAFT polymerization.ith terminal carboxylic acid group exhibited substantially lower haemolytic activity than
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To date, no study has examined the in vivo toxicity of RAFT polymers
alone. Several studies do, however, explore the use of RAFT polymers to
deliver biologically active compounds (e.g. nucleic acids, therapeutic
proteins and chemotherapeutic agents). Though they don't explicitly
evaluate the systemic effects of RAFT polymers on whole, vertebrate or-
ganisms, valuable insight can be gained from the observations made.
Listed in Table 1 are selected studies wherein RAFT-derived polymers
were applied in vivo without any apparent toxicity. While not an ex-
haustive list, the references contained therein are representative of
the literature generally in that various animal models have been used
to test the efﬁcacy of various polymers in differing applications. Yet no
reference was found to describe deleterious effects associated with the
RAFT technology. It is important, again, to note that side effects from
the polymers was not a focus of any of these papers, and so conclusions
drawn in that regardmust bemade very carefully. Nevertheless, the ab-
sence of notable reactions to RAFT polymers is suggestive of a general
in vivo compatibility.
5. Conclusions
RAFT-mediated polymerization has providedmeans to generate low
dispersity, molecular weight controlled polymers of various architec-
tures. These polymers have been employed in virtually all biomedical
applications where synthetic polymers are utilized. Moreover, RAFT
has opened the door for new applications of synthetic polymers as
biomaterials. One reason for the popularity of RAFT techniques is the
versatility that the RAFT agents provide. RAFT polymerization aids
drug delivery via enabling the facile conjugation to as well as the direct
grafting from therapeutic agents to create drug-polymer conjugates
with improved pharmacokinetic characteristics. RAFT polymerization
enables the synthesis of polymers of complex architecture that may
self-assemble into higher order structures to aid in the protection and
delivery of hydrophobic or hydrophilic small molecules, as well as
bioactive macromolecules such as polysaccharides, proteins, or nucleic
acids. RAFT-mediated synthesis of polymers has mitigated the intrinsic
toxicities of polymeric nucleic acid delivery vectors generally by provid-
ing researchers with a tool to ﬁnely tune molecular weight and
dispersity as well as to generate libraries of polymers and polymeric
structureswherewith to optimize delivery and cell viability. The natural
ﬁt of RAFT methods with biomedical materials research and production
has, very reasonably, led to concern of potential toxic effects associated
with the technology. Because of the myriad of combinations of Z
and R groups, the list of possible RAFT agents is extensive. The cyto-
compatibility of polymers prepared using dithiobenzoate and
trithiocarbonate RAFT agents have been explored in vitro and a consid-
erable body of literature describes the application of such polymers in
in vivo studies. While at high doses in vitro (200–1000 μM), typically or-
ders of magnitude higher than those concentrations examined in vivo),
dithiobenzoate terminated polymers can exhibit cytotoxicity, no reportTable 1
List of selected studies demonstrating in vivo application of RAFT polymers. No paper not-
ed increased toxicity.
Application RAFT Agent Removal Animal model References
Cancer drug delivery Dithiobenzoate No Mouse [76]
Cancer drug delivery Dithiobenzoate Yes Mouse [72]
Cancer drug delivery Dithiobenzoate No Mouse [77]
Cancer drug delivery Trithiocarbonate Possibly Mouse [78]
In vivo imaging Dithiobenzoate Yes Mouse [79]
In vivo imaging Dithiobenzoate Yes Rat [80]
Nucleic acid delivery Dithiobenzoate No Mouse [48]
Nucleic acid delivery Trithiocarbonate No Chicken embryo [81]
Protein delivery Trithiocarbonate No Mouse [82]
Drug delivery Trithiocarbonate No Mouse [83]
Nucleic acid delivery Dithiobenzoate Likely Mouse [47]has been found demonstrating cytotoxicity of a RAFT polymer attribut-
able to trithiocarbonate termini of polymers at similar concentrations.
While few cytotoxic effects have been demonstrated, subtler, unob-
served effects cannot be ruled out. For this reason, RAFT group removal
may be advisable, depending on the RAFT agent employed, for either
in vitro or in vivo applications. While applications of RAFT polymers in
the biomedical ﬁeld have increased dramatically, the current under-
standing of the cyto-compatibility of the RAFT generated materials is
incomplete. However, the low apparent toxicity of trithiocarbonate
RAFT polymers and the ease of removal of all RAFT groups suggest
that RAFT polymerization is amenable to virtually any biomedical
application where polymers of deﬁned composition, dispersity and
molecular weight are required.
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